Health Care

Discover how Bayer’s new subsidiary, Ruveon LLC, centralizes U.S. glyphosate sales to cut costs, mitigate legal risk, and stay competitive in a shifting crop‑science market.

Merck KGaA’s July 2026 stock dip reveals how its robust patent strategy, digital‑health investments, and strong cash flow position it to beat rising EU pricing pressures and stay ahead in oncology and metabolic markets.

UnitedHealth Group (UNH) projects a 20% Q2 EPS jump and 39% yearly rise, with Optum Health driving margin recovery and robust investor confidence.

Pfizer’s July 2026 insider‑holding filings show steady leadership ownership while hinting at future oncology CRO collaborations to speed drug‑development and cut costs.

Johnson & Johnson beats 2026 Q2 earnings estimates, driving $36.1B in revenue with strong pharma, medical devices and consumer health growth.

Explore how private bond placements help pharma & biotech finance drug development, navigate patent cliffs, M&A, and HTA to boost ROI.

Amgen faces FDA and EMA withdrawal of Tavneos after NEJM retraction, with data integrity and liver‑injury concerns highlighted.

Fosun Pharma gains NMPA approval for a new TCM granule, opening a $120 B market and positioning the company for growth while highlighting regulatory, IP, and cash‑flow risks.

Novonesis analysts lift target prices—Jefferies, BørsHus and Deutsche Bank now forecast up to 490 kr, backing a bullish stance amid modest share gains.

London market reacts to copper surge, defence spending and Cevian’s 13% stake at Smith & Nebhew, revealing new risks and growth prospects for investors.